CoChat

CDKN2A-Inactivated Pancreatic Ductal Adenocarcinoma Exhibits Therapeutic Sensitivity to Paclitaxel: A Bioinformatics Study

Open access
Lin, Jiunn-Chang, Liu, Tsang-Pai, Yang, Pei-Ming · 2020 · Journal of Clinical Medicine

The DOI matches its Crossref record; 31 of the 33 references it cites were found in a registry or an index.

Abstract

The mutation of cyclin dependent kinase inhibitor 2A (CDKN2A) is frequently found in pancreatic ductal adenocarcinoma (PDAC). However, its prognostic and therapeutic roles in PDAC have not been extensively investigated yet. In this study, we mined and integrated the cancer genomics and chemogenomics data to investigate the roles of CDKN2A genetic alterations in PDAC patients’ prognosis and treatment. We found that functional CDKN2A inactivation caused by mutations and deep deletions predicted poor prognosis in PDAC patients. CDKN2A inactivation was associated with the upregulation of genes related to estrogen response, which can be overcome by CDKN2A restoration. Chemosensitivity profiling of PDAC cell lines and patient-derived organoids found that CDKN2A inactivation was associated with the increased sensitivity to paclitaxel and SN-38 (the active metabolite of irinotecan). However, only paclitaxel can mimic the effect of CDKN2A restoration, and its drug sensitivity was correlated with genes related to estrogen response. Therefore, our study suggested that CDKN2A-inactivated PDAC patients could benefit from the precision treatment with paclitaxel, whose albumin-stabilized nanoparticle formulation (nab-paclitaxel) has been approved for treating PDAC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/jcm9124019

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The clinical impact for the loss of cyclin dependent kinase inhibitor 2A (CDKN2A) functional activity in pancreatic ductal adenocarcinoma. (a) The genetic alterations and mRNA expression levels of CDKN2A gene in 168 pancreatic ductal adenocarcinoma (PDAC) patients; (b) the correlation between CDKN2A genetic alterations (WT for wildtype; MUT for mutation; LOSS for shallow deletion; and DEEP LOSS for deep deletion) and CDKN2A mRNA expression levels; (c) the correlation between CDKN2A mRNA levels and PDAC patients’ overall survivals; (d) the correlation between CDKN2A genetic alterations (WT; MUT; LOSS; and DEEP LOSS) and PDAC patients’ overall survivals; (e) the correlation between CDKN2A genetic alterations and PDAC patients’ primary therapy outcomes (PD for progressive disease; SD for stable disease; PR for partial remission/response; and CR for complete remission/response); (f) the correlation between CDKN2A genetic alterations (MUT + DEEP LOSS vs. WT + LOSS) and PDAC patients’ overall survivals; (g) the correlation between CDKN2A genetic alterations (MUT + DEEP LOSS vs. WT + LOSS) and PDAC patients’ primary therapy outcomes.
Figure 1 The clinical impact for the loss of cyclin dependent kinase inhibitor 2A (CDKN2A) functional activity in pancreatic ductal adenocarcinoma. (a) The genetic alterations and mRNA expression levels of CDKN2A gene in 168 pancreatic ductal adenocarcinoma (PDAC) patients; (b) the correlation between CDKN2A genetic alterations (WT for wildtype; MUT for mutation; LOSS for shallow deletion; and DEEP LOSS for deep deletion) and CDKN2A mRNA expression levels; (c) the correlation between CDKN2A mRNA levels and PDAC patients’ overall survivals; (d) the correlation between CDKN2A genetic alterations (WT; MUT; LOSS; and DEEP LOSS) and PDAC patients’ overall survivals; (e) the correlation between CDKN2A genetic alterations and PDAC patients’ primary therapy outcomes (PD for progressive disease; SD for stable disease; PR for partial remission/response; and CR for complete remission/response); (f) the correlation between CDKN2A genetic alterations (MUT + DEEP LOSS vs. WT + LOSS) and PDAC patients’ overall survivals; (g) the correlation between CDKN2A genetic alterations (MUT + DEEP LOSS vs. WT + LOSS) and PDAC patients’ primary therapy outcomes.CC BY · PubMed Central
Figure 2 The functional impact of CDKN2A inactivation in pancreatic ductal adenocarcinoma. (a) Gene set enrichment analysis (GSEA) was performed against 50 cancer hallmarks. The blue bars indicate the enrichment results for CDKN2A-inactivated (“MUT + DEEP LOSS” vs. “WT + LOSS”) PDAC patients. The red bars indicate the results for CDKN2A restoration in CDKN2A-deleted PDAC cell line, CAPAN-1 (CDKN2A plasmid transfection vs. vector transfection). The blue or red bars highlighted in thick frames indicate that the cancer hallmarks were significantly enriched (p < 0.05); (b) the enrichment plots for “ESTROGEN_RESPONSE_EARLY” cancer and “ESTROGEN_RESPONSE_LATE” hallmarks.
Figure 2 The functional impact of CDKN2A inactivation in pancreatic ductal adenocarcinoma. (a) Gene set enrichment analysis (GSEA) was performed against 50 cancer hallmarks. The blue bars indicate the enrichment results for CDKN2A-inactivated (“MUT + DEEP LOSS” vs. “WT + LOSS”) PDAC patients. The red bars indicate the results for CDKN2A restoration in CDKN2A-deleted PDAC cell line, CAPAN-1 (CDKN2A plasmid transfection vs. vector transfection). The blue or red bars highlighted in thick frames indicate that the cancer hallmarks were significantly enriched (p < 0.05); (b) the enrichment plots for “ESTROGEN_RESPONSE_EARLY” cancer and “ESTROGEN_RESPONSE_LATE” hallmarks.CC BY · PubMed Central
Figure 3 Chemosensitivity profiles in CDKN2A-inactivated PDAC cell lines and patient-derived organoids. (a) The correlation between CDKN2A gene copy numbers and drug sensitivities in PDAC cell lines were obtained from the CTRP data via the CellMinerCDB website. Sensitive drugs correlated with low CDKN2A gene copy numbers are shown; (b) drug response data in PDAC patient-derived organoids were obtained from the supplementary materials in a previous study (reference [23]). Lower area under the curve (AUC) values indicated that the organoids were more sensitive to drug treatment.
Figure 3 Chemosensitivity profiles in CDKN2A-inactivated PDAC cell lines and patient-derived organoids. (a) The correlation between CDKN2A gene copy numbers and drug sensitivities in PDAC cell lines were obtained from the CTRP data via the CellMinerCDB website. Sensitive drugs correlated with low CDKN2A gene copy numbers are shown; (b) drug response data in PDAC patient-derived organoids were obtained from the supplementary materials in a previous study (reference [23]). Lower area under the curve (AUC) values indicated that the organoids were more sensitive to drug treatment.CC BY · PubMed Central
Figure 4 Paclitaxel treatment mimics the effect of CDKN2A restoration. (a) CMap analysis was performed to explore the similarity among CDKN2A- and drug-induced gene signatures; (b,c) the sensitive and resistant gene factors for paclitaxel (b) and SN-38 (c) in PDAC cell lines were obtained from the CTRP database via an online tool, the CellMinerCDB. GSEA was performed for these factors against 50 cancer hallmarks.
Figure 4 Paclitaxel treatment mimics the effect of CDKN2A restoration. (a) CMap analysis was performed to explore the similarity among CDKN2A- and drug-induced gene signatures; (b,c) the sensitive and resistant gene factors for paclitaxel (b) and SN-38 (c) in PDAC cell lines were obtained from the CTRP database via an online tool, the CellMinerCDB. GSEA was performed for these factors against 50 cancer hallmarks.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 46

Metadata

Authors
Lin, J.-C., Liu, T.-P., & Yang, P.-M.
Affiliations
  • Mackay Memorial Hospital (TW)
  • Wan Fang Hospital (TW)
Corresponding author
Yang, Pei-Ming
Venue
Journal of Clinical Medicine
Publisher
MDPI AG
Published
2020-12-12
Volume
9
Issue
12
Pages
4019
ISSN
2077-0383 (ISSN-L)
OpenAlex
W3113368844
Cited by
46
References
33
Citations by year
2026: 3 · 2025: 5 · 2024: 7 · 2023: 5 · 2022: 16 · 2021: 10
FWCI
2.80
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Ministry of Science and Technology, Taiwan (MOST109-2314-B-038-040, MOST109-2314-B-195-006)
  • The health and welfare surcharge of tobacco products in Taiwan (MOHW109-TDU-B-212-134020)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
CDKN2A, pancreatic ductal adenocarcinoma, paclitaxel, chemosensitivity, prognostic factors, SN-38, irinotecan, patient-derived organoids, nab-paclitaxel, CDKN2A mutation, CDKN2A deletion

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CDKN2A-Inactivated Pancreatic Ductal Adenocarcinoma Exhibits Therapeutic Sensitivity to Paclitaxel: A Bioinformatics Study. https://app.cochat.ai/papers/10.3390/jcm9124019
The paper
Lin, J.-C., Liu, T.-P., & Yang, P.-M. (2020). CDKN2A-Inactivated Pancreatic Ductal Adenocarcinoma Exhibits Therapeutic Sensitivity to Paclitaxel: A Bioinformatics Study. Journal of Clinical Medicine. https://doi.org/10.3390/jcm9124019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.